1
|
Cong D, Song J, Liu Y, Tan Y, Xue W, Liu X, Qi W, Lu J, Yuan X, Zhou Y, Hui AM, Li K. Pharmacokinetics, Pharmacodynamics, and Tolerability of Opicapone in Healthy Chinese and Caucasian Subjects: An Open-Label, Single-Center, Phase 1 Study. Neurol Ther 2022; 11:283-301. [PMID: 35006479 PMCID: PMC8743745 DOI: 10.1007/s40120-021-00314-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/15/2021] [Accepted: 12/08/2021] [Indexed: 11/28/2022] Open
Abstract
INTRODUCTION This study evaluated the pharmacokinetics (PK) and pharmacodynamics (PD) of single and multiple doses of opicapone (OPC) in healthy Chinese and Caucasian subjects. METHODS In this open-label, single-center, phase 1 study, eligible Chinese subjects received one of three OPC doses (25, 50, or 100 mg), and Caucasian subjects received either 25 or 50 mg of OPC. All subjects were administered a single dose of OPC, whereas subjects in the 50-mg OPC group continued to receive once-daily doses of 50 mg OPC for 10 days. The primary endpoint was to evaluate and compare the plasma concentrations and PK parameters of OPC and its main metabolite, and erythrocyte-soluble catechol-O-methyltransferase (S-COMT) activity in Chinese subjects with that of Caucasian subjects. The secondary endpoint was to evaluate the safety of OPC in Chinese subjects. The estimated results for geometric mean ratios (GMRs) were evaluated with the standard bioequivalence (BE) limits between 80% and 125% to evaluate the ethnic differences. All statistical analyses were performed using SAS version 9.4. RESULTS In total, 70 subjects (45 Chinese, 25 Caucasian) were enrolled; the majority of them were male (85.7%). The plasma exposure of both OPC and BIA 9-1103 increased in an approximately dose-proportional manner in both populations. Maximum S-COMT inhibition ranged from 79% to 95% after a single dose and was about 94% after a 10-day once-daily regimen in both populations. The point estimates of GMRs (Chinese/Caucasian) and 90% CI, except Cmax in 25-mg and 50-mg OPC groups, for PK and PD parameters were within 80% to 125%. Furthermore, no new risks or safety concerns associated with OPC were identified, indicating a tolerable safety profile in healthy Chinese subjects. CONCLUSION Ethnicity had no significant impact on PK and PD parameters after single or multiple doses of OPC, and OPC was safe and tolerable in healthy Chinese subjects. TRIAL REGISTRATION ChiCTR number, CTR20192230.
Collapse
Affiliation(s)
- Duanduan Cong
- Clinical Trial Center, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Assessment of Clinical Drugs Risk and Individual Application Key Laboratory, No. 1 Dahua Road, Dongdan Dongcheng District, Beijing, 100005, China
| | - Jie Song
- Clinical Research Department, Shanghai Fosun Pharmaceutical Development, Co., Ltd., Shanghai, 200000, China
| | - Yue Liu
- Clinical Trial Center, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Assessment of Clinical Drugs Risk and Individual Application Key Laboratory, No. 1 Dahua Road, Dongdan Dongcheng District, Beijing, 100005, China
| | - Yan Tan
- Clinical Research Department, Shanghai Fosun Pharmaceutical Development, Co., Ltd., Shanghai, 200000, China
| | - Wei Xue
- Clinical Trial Center, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Assessment of Clinical Drugs Risk and Individual Application Key Laboratory, No. 1 Dahua Road, Dongdan Dongcheng District, Beijing, 100005, China
| | - Xiaohui Liu
- Clinical Trial Center, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Assessment of Clinical Drugs Risk and Individual Application Key Laboratory, No. 1 Dahua Road, Dongdan Dongcheng District, Beijing, 100005, China
| | - Wenyuan Qi
- Clinical Trial Center, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Assessment of Clinical Drugs Risk and Individual Application Key Laboratory, No. 1 Dahua Road, Dongdan Dongcheng District, Beijing, 100005, China
| | - Jun Lu
- Clinical Research Department, Shanghai Fosun Pharmaceutical Development, Co., Ltd., Shanghai, 200000, China
| | | | | | - Ai-Min Hui
- Clinical Research Department, Shanghai Fosun Pharmaceutical Development, Co., Ltd., Shanghai, 200000, China.
| | - Kexin Li
- Clinical Trial Center, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Assessment of Clinical Drugs Risk and Individual Application Key Laboratory, No. 1 Dahua Road, Dongdan Dongcheng District, Beijing, 100005, China.
| |
Collapse
|
2
|
Ettcheto M, Busquets O, Sánchez-Lopez E, Cano A, Manzine PR, Verdaguer E, Olloquequi J, Auladell C, Folch J, Camins A. The preclinical discovery and development of opicapone for the treatment of Parkinson's disease. Expert Opin Drug Discov 2020; 15:993-1004. [PMID: 32450711 DOI: 10.1080/17460441.2020.1767580] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
INTRODUCTION Opicapone (OPC) is a well-established catechol-O-methyltransferase (COMT) inhibitor that is approved for the treatment of Parkinson's disease (PD) associated with L-DOPA/L-amino acid decarboxylase inhibitor (DDI) therapy allowing for prolonged activity due to a more continuous supply of L-DOPA in the brain. Thus, OPC decreases fluctuation in L-DOPA plasma levels and favors more constant central dopaminergic receptor stimulation, thus improving PD symptomatology. AREAS COVERED This review evaluates the preclinical development, pharmacology, pharmacokinetics and safety profile of OPC. Data was extracted from published preclinical and clinical studies published on PUBMED and SCOPUS (Search period: 2000-2019). Clinical and post-marketing data are also evaluated. EXPERT OPINION OPC is a third generation COMT inhibitor with a novel structure. It has an efficacy and tolerability superior to its predecessors, tolcapone (TOL) and entacapone (ENT). It also provides a safe and simplified drug regimen that allows neurologists to individually adjust the existing daily administration of L-DOPA. OPC is indicated as an adjunctive therapy to L-DOPA/DDI in patients with PD and end-of-dose motor fluctuations who cannot be stabilized on those combinations.
Collapse
Affiliation(s)
- Miren Ettcheto
- Departament of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy and Food Science, University of Barcelona , Barcelona, Spain.,Department of Biochemistry and Biotechnology, Faculty of Medicine and Life Science, University Rovira i Virgili , Reus, Spain.,Biomedical Research Networking Centre in Neurodegenerative Diseases (CIBERNED) , Madrid, Spain.,Institute of Neuroscience, University of Barcelona , Barcelona, Spain
| | - Oriol Busquets
- Departament of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy and Food Science, University of Barcelona , Barcelona, Spain.,Department of Biochemistry and Biotechnology, Faculty of Medicine and Life Science, University Rovira i Virgili , Reus, Spain.,Biomedical Research Networking Centre in Neurodegenerative Diseases (CIBERNED) , Madrid, Spain.,Institute of Neuroscience, University of Barcelona , Barcelona, Spain
| | - Elena Sánchez-Lopez
- Institute of Neuroscience, University of Barcelona , Barcelona, Spain.,Institute of Nanoscience and Nanotechnology (IN2UB), University of Barcelona , Barcelona, Spain.,Department of Pharmacy, Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy and Food Science, University of Barcelona , Barcelona, Spain
| | - Amanda Cano
- Institute of Neuroscience, University of Barcelona , Barcelona, Spain.,Institute of Nanoscience and Nanotechnology (IN2UB), University of Barcelona , Barcelona, Spain.,Department of Pharmacy, Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy and Food Science, University of Barcelona , Barcelona, Spain
| | - Patricia R Manzine
- Departament of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy and Food Science, University of Barcelona , Barcelona, Spain.,Biomedical Research Networking Centre in Neurodegenerative Diseases (CIBERNED) , Madrid, Spain.,Institute of Neuroscience, University of Barcelona , Barcelona, Spain.,Department of Gerontology, Federal University of São Carlos (Ufscar) , São Carlos, Brazil
| | - Ester Verdaguer
- Biomedical Research Networking Centre in Neurodegenerative Diseases (CIBERNED) , Madrid, Spain.,Institute of Neuroscience, University of Barcelona , Barcelona, Spain.,Department of Cellular Biology, Physiology and Immunology, Faculty of Biology, University of Barcelona , Barcelona, Spain
| | - Jordi Olloquequi
- Laboratory of Cellular and Molecular Pathology, Instituto de Ciencias Biomédicas, Facultad de Ciencias de la Salud, Universidad Autónoma de Chile , Talca, Chile
| | - Carme Auladell
- Biomedical Research Networking Centre in Neurodegenerative Diseases (CIBERNED) , Madrid, Spain.,Institute of Neuroscience, University of Barcelona , Barcelona, Spain.,Department of Cellular Biology, Physiology and Immunology, Faculty of Biology, University of Barcelona , Barcelona, Spain
| | - Jaume Folch
- Department of Biochemistry and Biotechnology, Faculty of Medicine and Life Science, University Rovira i Virgili , Reus, Spain.,Biomedical Research Networking Centre in Neurodegenerative Diseases (CIBERNED) , Madrid, Spain
| | - Antoni Camins
- Departament of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy and Food Science, University of Barcelona , Barcelona, Spain.,Biomedical Research Networking Centre in Neurodegenerative Diseases (CIBERNED) , Madrid, Spain.,Institute of Neuroscience, University of Barcelona , Barcelona, Spain.,Laboratory of Cellular and Molecular Pathology, Instituto de Ciencias Biomédicas, Facultad de Ciencias de la Salud, Universidad Autónoma de Chile , Talca, Chile
| |
Collapse
|